The use of dyslipidemic hamsters to evaluate drug-induced alterations in reverse cholesterol transport

Current Opinion in Investigational Drugs

Volumn 11, Issue 3, 2010, Pages 289-297

  Briand, François ^a  

^a Physiogenex SAS   (France)

Author keywords

Atherosclerosis; Cardiovascular disease; CETP; Hamster; HDL; Reverse cholesterol transport

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ANTILIPEMIC AGENT; ATORVASTATIN; BMS 212122; CGS 25159; CHENODEOXYCHOLIC ACID; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; GW 683965A; KY 455; LIVER X RECEPTOR AGONIST; LXR 623; MEVINOLIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TP2; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PRAVASTATIN; R 755; ROSIGLITAZONE; SQUALENE SYNTHASE INHIBITOR; TORCETRAPIB; UNCLASSIFIED DRUG; WAY 252623; YM 53601;

ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; DISEASE MODEL; DRUG MECHANISM; DYSLIPIDEMIA; HAMSTER; HUMAN; LIPID DIET; LIPOPROTEIN METABOLISM; LIVER METABOLISM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE CHOLESTEROL TRANSPORT; REVIEW;

ANIMALS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CRICETINAE; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; HUMANS;

EID: 77649102918     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Cuchel M, Rader DJ: Macrophage reverse cholesterol transport: Key to the regression of atherosclerosis? Circulation (2006) 113(21):2548-2555.
2. Miller GJ, Miller NE: Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet (1975) 1(7897):16-19.
3. Miller NE, La Ville A, Crook D: Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature (1985) 314(6006):109-111.
4. Escolà-Gil JC, Rotllan N, Julve J, Blanco-Vaca F: In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection. Atherosclerosis (2009) 206(2):321-327.
5. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denèfle P, Assmann G: Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet (1999) 22(4): 352-355.
6. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J: The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res (1997) 38(2):191-205.
7. Calabresi L, Baldassarre D, Castelnuovo S, Conca P, Bocchi L, Candini C, Frigerio B, Amato M, Sirtori CR, Alessandrini P, Arca M et al: Functional lecithin:cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation (2009) 120(7):628-635.
8. Furuyama S, Uehara Y, Zhang B, Baba Y, Abe S, Iwamoto T, Miura S, Saku K: Genotypic effect of ABCG1 gene promoter -257T
9. Van Eck M, Pennings M, Hoekstra M, Out R, Van Berkel TJ: Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol (2005) 16(3):307-315.
10. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ: Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest (2005) 115(10): 2870-2874.
11. Schwartz CC, VandenBroek JM, Cooper PS: Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res (2004) 45(9):1594-1607.
12. Ouguerram K, Krempf M, Maugeais C, Maugère P, Darmaun D, Magot T: A new labeling approach using stable isotopes to study in vivo plasma cholesterol metabolism in humans. Metabolism (2002) 51(1):5-11.
13. Sehayek E, Hazen SL: Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol (2008) 28(7):1296-1297.
14. Briand F, Naik SU, Fuki I, Millar JS, Macphee C, Walker M, Billheimer J, Rothblat G, Rader DJ: Both the peroxisome proliferatoractivated receptor δ agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Clin Trans Sci (2009) 2(2):127-133.
15. van der Velde AE, Vrins CL, van den Oever K, Seemann I, Oude Elferink RP, van Eck M, Kuipers F, Groen AK: Regulation of direct transintestinal cholesterol excretion in mice. Am J Physiol Gastrointest Liver Physiol (2008) 295(1):G203-G208.
16. Férézou J, Coste T, Chevallier F: Origins of neutral sterols in human feces studied by stable isotope labeling (D and 13C). Existence of an external secretion of cholesterol. Digestion (1981) 21(5):232-243.
17. Stein Y, Dabach Y, Hollander G, Stein O: Cholesteryl ester transfer activity in hamster plasma: Increase by fat and cholesterol rich diets. Biochim Biophys Acta (1990) 1042(1): 138-141.
18. Spady DK, Dietschy JM: Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat. J Lipid Res (1983) 24(3):303-315.
19. Liu GL, Fan LM, Redinger RN: The association of hepatic apoprotein and lipid metabolism in hamsters and rats. Comp Biochem Physiol A Comp Physiol (1991) 99(1-2):223-228.
20. Lewis GF, Murdoch S, Uffelman K, Naples M, Szeto L, Albers A, Adeli K, Brunzell JD: Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone. Diabetes (2004) 53(11):2893-2900.
21. Briand F, Treguier M, Andre A, Grillot D, Issandou M, Ouguerram K, Sulpice T: Liver X receptor activation promotes macrophageto- feces reverse cholesterol transport in a dyslipidemic hamster model. J Lipid Res (2009):doi:10.1194/jlr.M001552.
22. Nistor A, Bulla A, Filip DA, Radu A: The hyperlipidemic hamster as a model of experimental atherosclerosis. Atherosclerosis (1987) 68(1-2):159-173.
23. Sleder J, Chen YD, Cully MD, Reaven GM: Hyperinsulinemia in fructose-induced hypertriglyceridemia in the rat. Metabolism (1980) 29(4):303-305.
24. Tobey TA, Mondon CE, Zavaroni I, Reaven GM: Mechanism of insulin resistance in fructose-fed rats. Metabolism (1982) 31(6):608-612.
25. Kasim-Karakas SE, Vriend H, Almario R, Chow LC, Goodman MN: Effects of dietary carbohydrates on glucose and lipid metabolism in golden Syrian hamsters. J Lab Clin Med (1996) 128(2):208-213.
26. Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, Lewis GF, Adeli K: Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular apoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem (2000) 275(12):8416-8425.
27. Qu S, Su D, Altomonte J, Kamagate A, He J, Perdomo G, Tse T, Jiang Y, Dong HH: PPARα mediates the hypolipidemic action of fibrates by antagonizing FoxO1. Am J Physiol Endocrinol Metab (2007) 292(2):E421-E434.
28. Haidari M, Leung N, Mahbub F, Uffelman KD, Kohen-Avramoglu R, Lewis GF, Adeli K: Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and apoB48-containing lipoprotein overproduction. J Biol Chem (2002) 277(35):31646-31655.
29. Bilz S, Samuel V, Morino K, Savage D, Choi CS, Shulman GI: Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am J Physiol Endocrinol Metab (2006) 290(4):E716-E722.
30. Basciano H, Federico L, Adeli K: Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (2005) 2:5-18.
31. Souidi M, Combettes-Souverain M, Milliat F, Eckhardt ER, Audas O, Dubrac S, Parquet M, Férézou J, Lutton C: Hamsters predisposed to sucrose-induced cholesterol gallstones (LPN strain) are more resistant to excess dietary cholesterol than hamsters that are not sensitive to cholelithiasis induction. J Nutr (2001) 131(6):1803-1811.
32. Izem L, Morton RE: Molecular cloning of hamster lipid transfer inhibitor protein (apolipoprotein F) and regulation of its expression by hyperlipidemia. J Lipid Res (2009) 50(4):676-684.
33. Basciano H, Miller AE, Naples M, Baker C, Kohen R, Xu E, Su Q, Allister EM, Wheeler MB, Adeli K: Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am J Physiol Endocrinol Metab (2009) 297(2):E462-E473.
34. Basciano H, Miller A, Baker C, Naples M, Adeli K: LXRα activation perturbs hepatic insulin signaling and stimulates production of apolipoprotein B-containing lipoproteins. Am J Physiol Gastrointest Liver Physiol (2009) 297(2):G323-G332.
35. Woollett LA, Spady DK, Dietschy JM: Mechanisms by which saturated triacylglycerols elevate the plasma low density lipoprotein-cholesterol concentration in hamsters. Differential effects of fatty acid chain length. J Clin Invest (1989) 84(1): 119-128.
36. Himber J, Missano B, Rudling M, Hennes U, Kempen HJ: Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets. J Lipid Res (1995) 36(7):1567-1585.
37. Valasek MA, Repa JJ, Quan G, Dietschy JM, Turley SD: Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. Am J Physiol Gastrointest Liver Physiol (2008) 295(4):G813-G822.
38. Rizvi F, Puri A, Bhatia G, Khanna AK, Wulff EM, Rastogi AK, Chander R: Antidyslipidemic action of fenofibrate in dyslipidemic-diabetic hamster model. Biochem Biophys Res Commun (2003) 305(2):215-222.
39. Wang PR, Guo Q, Ippolito M, Wu M, Milot D, Ventre J, Doebber T, Wright SD, Chao YS: High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor α selective agonists. Eur J Pharmacol (2001) 427(3):285-293.
40. Krause BR, Princen HM: Lack of predictability of classical animal models for hypolipidemic activity: A good time for mice? Atherosclerosis (1998) 140(1):15-24.
41. Suckling KE, Benson GM, Bond B, Gee A, Glen A, Haynes C, Jackson B: Cholesterol lowering and bile acid excretion in the hamster with cholestyramine treatment. Atherosclerosis (1991) 89(2-3):183-190.
42. Groot PH, Pearce NJ, Suckling KE, Eisenberg S: Effects of cholestyramine on lipoprotein levels and metabolism in Syrian hamsters. Biochim Biophys Acta (1992) 1123(1):76-84.
43. Sawada M, Matsuo M, Seki J: Inhibition of cholesterol synthesis causes both hypercholesterolemia and hypocholesterolemia in hamsters. Biol Pharm Bull (2002) 25(12):1577-1582.
44. Amin D, Gustafson S, Perrone MH: Lovastatin is hypertriglyceridemic in Syrian golden hamsters. Biochem Biophys Res Commun (1988) 157(2):530-534.
45. Ugawa T, Kakuta H, Moritani H, Inagaki O: Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters. Br J Pharmacol (2002) 137(4):561-569.
46. Doebber TW, Kelly LJ, Zhou G, Meurer R, Biswas C, Li Y, Wu MS, Ippolito MC, Chao YS, Wang PR, Wright SD et al: MK-0767, a novel dual PPARβ/δ agonist, displays robust antihyperglycemic and hypolipidemic activities. Biochem Biophys Res Commun (2004) 318(2):323-328.
47. Zuckerman SH, Evans GF: Cholesteryl ester transfer protein inhibition in hypercholesterolemic hamsters: Kinetics of apoprotein changes. Lipids (1995) 30(4):307-311.
48. Kothari HV, Poirier KJ, Lee WH, Satoh Y: Inhibition of cholesterol ester transfer protein CGS 25159 and changes in lipoproteins in hamsters. Atherosclerosis (1997) 128(1):59-66.
49. Tchoua U, D'Souza W, Mukhamedova N, Blum D, Niesor E, Mizrahi J, Maugeais C, Sviridov D: The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res (2008) 77(4):732-739.
50. Zhang AH, Gao S, Fan JL, Huang W, Zhao TQ, Liu G: Increased plasma HDL cholesterol levels and biliary cholesterol excretion in hamster by LCAT overexpression. FEBS Lett (2004) 570(1-3):25-29.
51. Robl JA, Sulsky R, Sun CQ, Simpkins LM, Wang T, Dickson JK Jr, Chen Y, Magnin DR, Taunk P, Slusarchyk WA, Biller SA et al: A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J Med Chem (2001) 44(6):851-856.
52. Nakamura S, Kamiya S, Shirahase H, Kanda M, Yoshimi A, Tarumi T, Kurahashi K: Hypolipidemic and antioxidant activity of the novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor KY-455 in rabbits and hamsters. Arzneimittelforschung (2004) 54(2):102-108.
53. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD et al: Role of LXRs in control of lipogenesis. Genes Dev (2000) 14(22):2831-2838.
54. Groot PH, Pearce NJ, Yates JW, Stocker C, Sauermelch C, Doe CP, Willette RN, Olzinski A, Peters T, d'Epagnier D, Morasco KO et al: Synthetic LXR agonists increase LDL in CETP species. J Lipid Res (2005) 46(10):2182-2191.
55. Quinet EM, Basso MD, Halpern AR, Yates DW, Sheffan RJ, Clerin V, Resmini C, Keith JC, Berrodin TJ, Feingold I, Zhong W et al: LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res (2009) 50(12):2358-2370.
56. Otto J, Ordovas JM, Smith D, van Dongen D, Nicolosi RJ, Schaefer EJ: Lovastatin inhibits diet induced atherosclerosis in F1B golden Syrian hamsters. Atherosclerosis (1995) 114(1): 19-28.
57. Ugawa T, Kakuta H, Moritani H, Shikama H: Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model. Br J Pharmacol (2002) 135(6): 1572-1578.
58. Mangaloglu L, Cheung RC, Van Iderstine SC, Taghibiglou C, Pontrelli L, Adeli K: Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: Evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. Metabolism (2002) 51(4):409-418.
59. Chong T, Naples M, Federico L, Taylor D, Smith GJ, Cheung RC, Adeli K: Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia. Atherosclerosis (2006) 185(1):21-31.
60. Evans GF, Bensch WR, Apelgren LD, Bailey D, Kauffman RF, Bumol TF, Zuckerman SH: Inhibition of cholesteryl ester transfer protein in normocholesterolemic and hypercholesterolemic hamsters: Effects on HDL subspecies, quantity, and apolipoprotein distribution. J Lipid Res (1994) 35(9):1634-1645.
61. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med (2004) 350(15):1505-1515.
62. Briand F, Grillot D, Issandou M, Sulpice T: Dyslipidemic hamster as a predictive model to evaluate drugs affecting HDL metabolism: Effects of CETP inhibitor torcetrapib and LXR agonist GW3965 on HDL-cholesteryl esters kinetics in vivo. Arterioscler Thromb Vasc Biol (2009) 29(e9):Abs P122.
63. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer JT, Rothblat GH, Rader DJ: Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation (2006) 113(1):90-97.
64. Matsui Y, Horiuchi K, Yamamoto K, Kanai K: Pharmacological properties of R-755, a novel acyl-CoA:cholesterol acyltransferase inhibitor, in cholesterol-fed rats, hamsters and rabbits. Jpn J Pharmacol (2001) 85(4):423-433.
65. van Heek M, Austin TM, Farley C, Cook JA, Tetzloff GG, Davis HR: Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes (2001) 50(6):1330-1335.